Novartis patent settlement on Gleevec with Sun Pharma subsidiary
The US unit of Swiss drug major Novartis (NOVN: VX) has settled its litigation with the US subsidiary of India’s Sun Pharmaceutical Industries (BSE: 524715) relating to Novartis patents covering the use of certain polymorphic forms of its cancer drug Gleevec (imatinib mesylate), which expire in 2019 (including pediatric exclusivity).
The basic compound patent for Gleevec expires in the USA on July 4, 2015. Sun Pharmaceutical’s shares rose 2% to 626 rupees on the Indian stock market after the announcement.
Sun can start selling generic in February 2016
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze